Capricor jumps after Phase 3 data show Deramiocel improves heart function and slows muscle decline in Duchenne muscular ...
The Company plans to submit its response to the CRL, including the results from the HOPE-3 trial, to address the Agency's previous requests for additional data.
Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...
In 105 boys and young men enrolled in the HOPE-3 trial, patients given deramiocel every three months for a year had 54% ...
Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key ...
Zacks Investment Research on MSN
CAPR stock skyrockets 282% in a week: Here's what you need to know
Shares of Capricor Therapeutics CAPR have skyrocketed 281.9% this week. The massive stock price surge was observed after the ...
Piper Sandler raised the firm’s price target on Capricor Therapeutics (CAPR) to $45 from $20 and keeps an Overweight rating on the shares. The ...
Shares quadrupled now that the company appears on track to reverse an earlier FDA rejection of what could be the first ...
Capricor Therapeutics shares gained after analysts said they believe the company can achieve profitability by 2028. The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the ...
Capricor Therapeutics has seen its modeled fair value estimate jump from about $20.60 to roughly $44.56 per share, as analysts grow more confident in Deramiocel's path from the clinic to ...
US rare diseases focused biotech Capricor Therapeutics shares closed up 371% at $29.96, having leapt a staggering 500% ...
Capricor Therapeutics (CAPR) announced that the European Medicines Agency, EMA, has granted both Orphan Drug and Advanced Therapy Medicinal Product, ATMP, designations to its lead asset, deramiocel, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback